|8th February 2021||Advisors Llc Perceptive||1,770,600||Conversion of derivative||$0.00|
|8th February 2021||Advisors Llc Perceptive||2,941,769||Conversion of derivative||$0.00|
|8th February 2021||Advisors Llc Perceptive||1,250,000||Open or private purchase||$16.00||$20,000,000.00|
|8th February 2021||Advisors Llc Perceptive||2,857,795||Conversion of derivative||$0.00|
|28th January 2021||Advisors Llc Perceptive||4,219,409||Open or private purchase||$2.37||$9,999,999.33|
|25th January 2021||Advisors Llc Perceptive||311,111||Open or private purchase||$22.50||$6,999,997.50|
|22nd January 2021||Advisors Llc Perceptive||33,849||Open or private sale||$8.95||$302,948.55|
|22nd January 2021||Advisors Llc Perceptive||285,151||Open or private sale||$8.16||$2,326,832.16|
|22nd January 2021||Advisors Llc Perceptive||550,000||Open or private sale||$1.48||$814,000.00|
|21st January 2021||Advisors Llc Perceptive||674,352||Open or private sale||$1.68||$1,132,911.36|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518.